Limits...
A new curcuma extract (flexofytol®) in osteoarthritis: results from a belgian real-life experience.

Appelboom T, Maes N, Albert A - Open Rheumatol J (2014)

Bottom Line: Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life.Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months.We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

View Article: PubMed Central - PubMed

Affiliation: University of Brussels, Belgium.

ABSTRACT
This retrospective observational study summarizes the experiences of 820 patients treated with a new Curcuma extract (Flexofytol®, 4-6 capsules per day), for more than 6 months for various forms of painful osteoarthritis. These experiences were reported by 110 Belgian general practitioners via a questionnaire that included quality-of-life parameters for assessing patient experience. Data were submitted to an independent statistician for analysis. Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life. Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs. Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months. These data must be confirmed with randomized controlled studies. We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

No MeSH data available.


Related in: MedlinePlus

Reductions in concomitant therapies were independent ofosteoarthritis location.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4209497&req=5

Figure 4: Reductions in concomitant therapies were independent ofosteoarthritis location.

Mentions: When patients were treated with Flexofytol®, they significantly reduced the number of additional treatments they took for osteoarthritis (p<0.0001; Fig. 4). This phenomenon was independent from the locations of pain (Fig. 4). However, the consumption of concomitant therapies remained elevated among patients suffering from pain in the spine (p=0.014) or the shoulder (p=0.040). It is interesting to note that the reduction in the use of concomitant therapies was statistically significant in the first 6 weeks after the initiation of Flexofytol® therapy (Fig. 4 and Table 2). In general, Flexofytol® allowed patients to reduce the number of other treatments of osteoarthritis, independent of the number of painful locations or concomitant therapies.


A new curcuma extract (flexofytol®) in osteoarthritis: results from a belgian real-life experience.

Appelboom T, Maes N, Albert A - Open Rheumatol J (2014)

Reductions in concomitant therapies were independent ofosteoarthritis location.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4209497&req=5

Figure 4: Reductions in concomitant therapies were independent ofosteoarthritis location.
Mentions: When patients were treated with Flexofytol®, they significantly reduced the number of additional treatments they took for osteoarthritis (p<0.0001; Fig. 4). This phenomenon was independent from the locations of pain (Fig. 4). However, the consumption of concomitant therapies remained elevated among patients suffering from pain in the spine (p=0.014) or the shoulder (p=0.040). It is interesting to note that the reduction in the use of concomitant therapies was statistically significant in the first 6 weeks after the initiation of Flexofytol® therapy (Fig. 4 and Table 2). In general, Flexofytol® allowed patients to reduce the number of other treatments of osteoarthritis, independent of the number of painful locations or concomitant therapies.

Bottom Line: Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life.Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months.We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

View Article: PubMed Central - PubMed

Affiliation: University of Brussels, Belgium.

ABSTRACT
This retrospective observational study summarizes the experiences of 820 patients treated with a new Curcuma extract (Flexofytol®, 4-6 capsules per day), for more than 6 months for various forms of painful osteoarthritis. These experiences were reported by 110 Belgian general practitioners via a questionnaire that included quality-of-life parameters for assessing patient experience. Data were submitted to an independent statistician for analysis. Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life. Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs. Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months. These data must be confirmed with randomized controlled studies. We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

No MeSH data available.


Related in: MedlinePlus